Anorexiants Market size to exceed USD 1.75 Billion by 2034

Selbyville, DE. - The global anorexiants market was estimated at USD 1.07 billion in 2024 and is expected to grow from USD 1.11 billion in 2025 to USD 1.75 billion by 2034, at a CAGR of 5.2%, according to the latest report published by Global Market Insights Inc.  

The global rise in obesity and overweight populations is one of the primary drivers of the anorexiants market. As lifestyle diseases like type 2 diabetes, hypertension, and cardiovascular diseases become more prevalent, demand for weight management drugs, including anorexiants, continues to grow.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 1.07 billion  
• 2025 Market Size: USD 1.11 billion  
• 2034 Forecast Market Size: USD 1.75 billion  
• CAGR (2025–2034): 5.2%  

• Regional Insights:

• Largest Market: North America  
• Fastest Growing Market: Asia Pacific  
• Emerging Countries: India, Brazil, Mexico, South Africa  

• Key Growth Drivers:

1. Growing awareness of weight-related health risks: Rising awareness about the health risks associated with excess weight, such as heart disease, stroke, and sleep apnea, is driving more individuals to seek effective weight-loss solutions, boosting the demand for anorexiants.  
2. Advances in drug formulations: Continuous innovation in anorexiants, with a focus on improving efficacy and minimizing side effects, is expanding treatment options.  
3. Government initiatives and healthcare support: Governments across the world are launching obesity management programs and encouraging weight-loss treatments, contributing to a more supportive regulatory environment for anorectic drugs.  
4. Rising adoption of lifestyle modification programs: The integration of anorexiants with lifestyle modification programs, such as dietary counseling and physical activity regimens, has increased their popularity, as patients see better results when drugs are combined with behavioral changes.  
5. Aging population and increased risk of obesity: The global aging population is particularly vulnerable to obesity, which is often exacerbated by factors like reduced metabolism and lack of physical activity.  

• Key Players:

• Novo Nordisk led the market with over ~15% share in 2024.  
• Some of the top players in this market include Currax Pharmaceuticals, Eli Lilly and Company, Pfizer, Novo Nordisk, and Lannett Company, which together held a 50-55% share in 2024.  

• Key Challenges

1. Safety and side effects concerns: Anorexiants often come with side effects such as elevated heart rate, hypertension, and nervous system issues, making patients wary of long-term usage.  
2. High cost of treatment: The cost of prescription weight-loss drugs can be prohibitive, particularly in countries without strong reimbursement policies.  
3. Stigma and psychological barriers: Despite increasing awareness, weight loss treatments still carry a social stigma, particularly for patients who may feel embarrassed or ashamed about using anorexiants.  
4. Regulatory and approval hurdles: Given the nature of anorexiants as controlled substances, the approval process can be long and complex.  
5. Competition from non-pharmaceutical solutions: Anorexiants face stiff competition from dietary plans, exercise programs, and non-prescription supplements, which are often seen as more accessible, cost-effective, and lower-risk options for weight loss.  

Browse key industry insights spread across 136 pages with 150 market data tables and figures from the report, “Anorexiants Market - By Drug Class, By Route of Administration, By Indication, By Drug Type, By Distribution Channel - Global Forecast, 2025 - 2034” in detail, along with the table of contents:  

Anorexiants Market Size, Share & Forecast Report, 2025-2034  

Rising Adoption of CNS Stimulants

The CNS stimulants segment generated significant revenues in 2024, driven by appetite suppression and weight management. Medications in this category, like phentermine and diethylpropion, work by increasing dopamine and norepinephrine levels in the brain, which suppresses appetite and promotes energy expenditure. This segment is expected to witness continued growth, particularly in the prescription weight loss space, as more patients turn to medications that can help them manage obesity and related conditions like type 2 diabetes.  

Oral to Gain Traction

The oral segment of the anorexiants market held a substantial share in 2024, driven by patient preference for easy-to-use, non-invasive treatments. Oral anorexiants like Orlistat and phentermine/topiramate have become popular choices due to their convenience, availability, and proven efficacy. These drugs are often prescribed as part of a broader weight management regimen that includes dietary changes and physical activity.  

Increasing Prevalence of Obesity

The obesity segment held a robust share in 2024, driven by the escalating global obesity crisis. With increasing rates of obesity linked to chronic diseases like hypertension, type 2 diabetes, and cardiovascular diseases, demand for effective weight-loss therapies is surging. Anorexiants in this segment are viewed as critical tools in the management of moderate to severe obesity, especially when lifestyle changes like diet and exercise alone are insufficient.  

North America to Emerge as a Lucrative Region

North America anorexiants market will grow at a decent CAGR during 2025-2034, owing to well-established healthcare infrastructure, high levels of healthcare spending, and increasing awareness about obesity-related health risks. As a result, North American companies are focusing on launching new anorexiants and leveraging direct-to-consumer marketing strategies to increase drug adoption.  

Major players in the anorexiants market are KVK-Tech, Teva Pharmaceuticals, Lannett Company, Novo Nordisk, Valeant Pharmaceuticals, Currax Pharmaceuticals, Eli Lilly and Company, Aventis Pharmaceuticals, Zydus Pharmaceuticals, Pfizer, and Vivus.  

To strengthen their presence and market foothold, companies in the anorexiants market are employing a variety of key strategies. These include innovative product development, particularly regarding combination therapies and non-stimulant formulations, which cater to different patient preferences and needs. Companies are also investing heavily in patient education and digital health solutions, such as apps and online counseling services, to increase treatment adherence and optimize weight loss outcomes.